# Levosimendan Versus Dobutamine for Renal Function in Heart Failure

> **NCT02133105** · PHASE3 · COMPLETED · sponsor: **Göteborg University** · enrollment: 33 (actual)

## Conditions studied

- Cardiorenal Syndrome

## Interventions

- **DRUG:** Levosimendan
- **DRUG:** Dobutamine

## Key facts

- **NCT ID:** NCT02133105
- **Lead sponsor:** Göteborg University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02133105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02133105, "Levosimendan Versus Dobutamine for Renal Function in Heart Failure". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02133105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*